Literature DB >> 22817262

Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice.

Xiaoying Bi1, Yanbo Zhang, Bin Yan, Shaokuan Fang, Jue He, Dai Zhang, Zhijun Zhang, Jiming Kong, Qingrong Tan, Xin-Min Li.   

Abstract

White matter impairment is a feature of vascular depression. The anti-psychotic quetiapine has been shown to enhance the therapeutic effects of anti-depressants on vascular depression, but the mechanism remains unknown. In this study, we found that 2 weeks of treatment with quetiapine prior to bilateral carotid artery occlusion and reperfusion, in an animal model of vascular depression, resulted in reduced myelin breakdown and oligodendrocyte loss compared to placebo-treated mice on post-operative day (POD) 7. For late stage of recovery (POD40), quetiapine treatment resulted in enhanced oligodendrocyte maturation relative to placebo. The results suggest that quetiapine is a potential intervention for oligodendrocyte damage and this may contribute to its anti-depressant effects through white matter protection in vascular depression.
© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22817262     DOI: 10.1111/j.1471-4159.2012.07883.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Cognitive impairment with and without depression history: an analysis of white matter microstructure.

Authors:  Shantel L Duffy; Matt Paradise; Ian B Hickie; Simon J G Lewis; Sharon L Naismith; Jim Lagopoulos
Journal:  J Psychiatry Neurosci       Date:  2014-03       Impact factor: 6.186

2.  [New therapeutic strategies for remyelination in multiple sclerosis].

Authors:  D Kremer; H-P Hartung; M Stangel; P Küry
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 3.  Current advancements in promoting remyelination in multiple sclerosis.

Authors:  David Kremer; Rainer Akkermann; Patrick Küry; Ranjan Dutta
Journal:  Mult Scler       Date:  2018-10-01       Impact factor: 6.312

4.  Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review).

Authors:  Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

5.  In Vivo Optical Imaging of Myelination Events in a Myelin Basic Protein Promoter-Driven Luciferase Transgenic Mouse Model.

Authors:  James Cao; Yanping Hu; Mohammed Salman Shazeeb; Carlos E Pedraza; Nilesh Pande; Daniel Weinstock; Gregory H Polites; Wenfei Zhang; Karen J Chandross; Xiaoyou Ying
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

6.  Minocycline Ameliorates Depressive-Like Behavior and Demyelination Induced by Transient Global Cerebral Ischemia by Inhibiting Microglial Activation.

Authors:  Bingying Du; Hailong Li; Huiwen Zheng; Cunxiu Fan; Meng Liang; Yongjie Lian; Zelan Wei; Yanbo Zhang; Xiaoying Bi
Journal:  Front Pharmacol       Date:  2019-10-22       Impact factor: 5.810

Review 7.  Promoting remyelination in multiple sclerosis-recent advances.

Authors:  E Jolanda Münzel; E Jolanda Münzel; Anna Williams
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

8.  Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions.

Authors:  Karen D Lariosa-Willingham; Elen S Rosler; Jay S Tung; Jason C Dugas; Tassie L Collins; Dmitri Leonoudakis
Journal:  BMC Res Notes       Date:  2016-09-05

Review 9.  The Current Challenges for Drug Discovery in CNS Remyelination.

Authors:  Sonia Balestri; Alice Del Giovane; Carola Sposato; Marta Ferrarelli; Antonella Ragnini-Wilson
Journal:  Int J Mol Sci       Date:  2021-03-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.